Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith M Regan

Showing results (11-20 of 259) with videos related to

Pageof 26
Sort By:
Breast (Edinburgh, Scotland)|January 17, 2026
Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancerCarmine Valenza, Ann H Partridge, Meredith M Regan
Breast (Edinburgh, Scotland)|April 24, 2016
Are SOFT and TEXT results practice changing and how?Olivia Pagani, Meredith M Regan, Prudence A Francis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2017
Reply to Y. Zhu et alWanling Xie, Meredith M Regan, Christopher J Sweeney
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern EraBenjamin Izar, Meredith M Regan, David F McDermott
European Urology|June 30, 2023
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116Meredith M Regan, Michael B Atkins, David F McDermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Challenges of guarantee-time biasAnita Giobbie-Hurder, Richard D Gelber, Meredith M Regan
Clinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B Atkins
The New England Journal of Medicine|April 23, 2015
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming
Urology|October 2, 2007
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapyTimothy J Daskivich, Meredith M Regan, William K Oh
The Journal of Urology|October 31, 2006
Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4Timothy J Daskivich, Meredith M Regan, William K Oh
Pageof 26

Showing results (11-20 of 259) with videos related to

Sort By:
Pageof 26
Breast (Edinburgh, Scotland)|January 17, 2026
Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancerCarmine Valenza, Ann H Partridge, Meredith M Regan
Breast (Edinburgh, Scotland)|April 24, 2016
Are SOFT and TEXT results practice changing and how?Olivia Pagani, Meredith M Regan, Prudence A Francis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2017
Reply to Y. Zhu et alWanling Xie, Meredith M Regan, Christopher J Sweeney
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern EraBenjamin Izar, Meredith M Regan, David F McDermott
European Urology|June 30, 2023
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116Meredith M Regan, Michael B Atkins, David F McDermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Challenges of guarantee-time biasAnita Giobbie-Hurder, Richard D Gelber, Meredith M Regan
Clinical Genitourinary Cancer|October 10, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott, Meredith M Regan, Michael B Atkins
The New England Journal of Medicine|April 23, 2015
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming
Urology|October 2, 2007
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapyTimothy J Daskivich, Meredith M Regan, William K Oh
The Journal of Urology|October 31, 2006
Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4Timothy J Daskivich, Meredith M Regan, William K Oh
Pageof 26